Last reviewed · How we verify

NCT07520422

Bacillus Coagulans Based Product in IBS-Diarrhea

Completed NA Last updated 9 April 2026
What this trial tests

NA trial testing Probiotic Arm in IBS-D (Diarrhea-predominant) in 50 participants. Completed in 25 May 2023.

Timeline
25 February 2023
Primary endpoint
25 May 2023
25 May 2023

Quick facts

Lead sponsorBioagile Therapeutics Pvt. Ltd.
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Enrollment50
Start date25 February 2023
Primary completion25 May 2023
Estimated completion25 May 2023
Sites1 location across India

Drugs / interventions tested

Conditions studied

Sponsor

Bioagile Therapeutics Pvt. Ltd. — full company profile →

Who can join

Adults 18 to 65, any sex, with IBS-D (Diarrhea-predominant). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective, randomized, double-blind, placebo-controlled, parallel-group interventional clinical trial designed to evaluate the efficacy and safety of a Bacillus coagulans-based product in adult patients with mild to moderate Irritable Bowel Syndrome with predominant diarrhea (IBS-D), diagnosed according to Rome III criteria. A total of 50 eligible male and female participants aged 18 to 65 years will be randomized in a 1:1 ratio to receive either Bacillus coagulans capsules or matching placebo for 8 weeks. The investigational product contains Bacillus coagulans (10⁶-10⁸ CFU) administered orally twice daily, morning and evening. The primary objective is to assess the effect of the study product on IBS-D symptoms, including abdominal pain, gastrointestinal symptom severity, stool consistency, and stool frequency, using validated assessment tools such as Abdominal Pain Visual Analogue Scale (VAS), IBS Symptom Severity Scale (IBS-SSS), and Bristol Stool Form Scale (BSFS). Secondary assessments include changes in hematological parameters and lipid profile biomarkers, along with safety monitoring through vital signs and adverse event reporting. Participants will attend four study visits: screening, baseline, Week 4, and Week 8. Weekly symptom recordings for abdominal pain and stool characteristics will be documented using participant diary cards throughout the treatment period.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Probiotic Arm

Trials testing the same drug.

Other recruiting trials for IBS-D (Diarrhea-predominant)

Currently open trials in the same condition.

Other Bioagile Therapeutics Pvt. Ltd. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07520422.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing